Structured abstract
Question
Does vasopressin, as the initial vasopressor, improve one-hour survival compared to epinephrine in inpatients with cardiac arrest?
Design
Multicentre, randomized controlled trial. Patients, caregivers, study investigators, and adjudication committee were blinded.
Setting
Emergency rooms, critical care units, and wards of three teaching hospitals in Canada from July 1997 to November 1998.
Patients
Two hundred inpatients with cardiac arrest from asystole, pulseless electrical activity, or refractory ventricular fibrillation. Exclusion criteria were age < 16 yr; documented terminal illness; do-not-resuscitate status; hospital admission < 24 hr after trauma; cardiac arrest before arrival to hospital, or in the operating, recovery, or delivery rooms, or from obvious exsanguination; or previous enrollment in the study. Study was approved by the research ethics committees; informed consent was not obtained.
Intervention
All patients were treated according to the American Heart Association Advanced Cardiac Life Support (ACLS) protocols. The intervention was applied whenever the ACLS protocol indicated epinephrine. One hundred and four patients were allocated to vasopressin 40 Uiv; 96 patients were allocated to epinephrine 1 mgiv. Both groups received epinephrine 1 mgiv every three to five minutes if there was no return of pulse.
Main outcomes
One-hour survival was the primary outcome. Survival to 24 hr, 30 days, and hospital discharge; cognitive function (mini-mental state examination and five-point cerebral performance score); return of pulse; and adverse events were secondary outcomes.
Main results
Analysis was per protocol. There were no differences in survival to one hour, 24 hr, 30 days, or hospital discharge, or in cognitive function, return of pulse, and adverse events between the two groups. The sample size was powered to detect a 20% absolute difference in one-hour survival.
Conclusion
Vasopressin neither improved nor worsened survival in cardiac arrest from asystole, pulseless electrical activity, or refractory ventricular fibrillation when compared with epinephrine.
Funding
Heart and Stroke Foundation of Canada.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. International Consensus on Science. Circulation 2000; 102 (Supplement I): II-I384.
Lindner KH, Dirks B, Strohmenger HU, Prengel AW, Lindner IM, Lurie KG Randomised comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation. Lancet 1997; 349: 535–7.
Stiell LG, Hebert PC, Wells GA, et al. Vasopressin versus epinephrine for inhospital cardiac arrest: a randomised controlled trial. Lancet 2001; 358: 105–9.
Wenzel V, Lindner KH, Krismer AC, Miller EA, Voelckel WG, Lingnau W. Repeated administration of vasopressin but not epinephrine maintains coronary perfusion pressure after early and late administration during prolonged cardiopulmonary resuscitation in pigs. Circulation 1999; 99: 1379–84.
References
Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. International Sonsensus on Science. Circulation 2000; 102 (Supplement I): II-I384.
Morris DC, Dereczyk BE, Grzybowski M, et al. Vasopressin can increase coronary perfusion pressure during human cardiopulmonary resuscitation. Acad Emerg Med 1997; 4: 878–83.
Babar SI, Berg RA, Hilwig RW, Kern KB, Ewy GA Vasopressin versus epinephrine during cardiopulmonary resuscitation: a randomized swine outcome study. Resuscitation 1999; 41: 185–92.
Wenzel V, Lindner KH. Employing vasopressin during cardiopulmonary resuscitation and vasodilatory shock as a lifesaving vasopressor. Cardiovasc Res 2001; 51: 529–41.
Lindner KH, Dirks B, Strohmenger HU, Prengel AW, Lindner IM, Lurie KG Randomised comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation. Lancet 1997; 349: 535–7.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Denault, A., Beaulieu, Y., Bélisle, S. et al. Best evidence in anesthetic practice Treatment: Vasopressin neither improves nor worsens survival from cardiac arrest. Can J Anesth 49, 312–314 (2002). https://doi.org/10.1007/BF03020534
Issue Date:
DOI: https://doi.org/10.1007/BF03020534